Drugs / Rotarix
Rotarix
also known as
Rotateq · Rotavirus vaccine · RV5 · RV1 · Rotavirus Vaccine, Live, Oral, Pentavalent · PRV · HRV · HRV vaccine · +11 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Rotashield | — | 1999-05-07 | europa.eu ↗ |
Trials 68 · started per year
today
EU approved 1999
2
4
1
3
5
2
9
3
8
4
3
2
4
2
1
1
2
3
4
2
2
1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01086436 | Mar → Apr 2010 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01162590 | Mar 2010 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00953056 | Sep 2009 → Mar 2010 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00981669 | Mar 2009 → Mar 2010 | Rotavirus infection | Butantan Institute | Completed | No outcome recorded |
| Phase 1 | NCT00836498 | Jan 2009 → Jan 2010 | Rotavirus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT04658914 | Apr 2021 → Aug 2022 | Rotavirus infection, diarrheal disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| Phase 2 | NCT04344054 | Feb 2021 → Sep 2022 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 2 | NCT04398706 | May 2020 → Aug 2023 | chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT02482636 | Aug 2015 → Nov 2017 | infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01049035 | Dec 2009 → Feb 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00880698 | Dec 2009 → Jan 2014 | HIV infectious disease, Rotavirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01377571 | Oct 2009 → Mar 2010 | diarrheal disease | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
| Phase 2 | NCT00432380 | Mar → Sep 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00263666 | Mar 2005 → Feb 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00383903 | Sep 2003 → Sep 2004 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00346892 | Nov 2001 → Mar 2003 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00385320 | May 2001 → Apr 2003 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00429481 | Jan 2001 → Apr 2003 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00729001 | Nov 2000 → Sep 2002 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00425737 | Aug 2000 → Jul 2001 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT06025695 | Sep 2023 → May 2024 | gastroenteritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04481191 | Aug 2020 → May 2021 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT04031846 | Sep 2019 → Aug 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03893448 | Jun 2019 → May 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03630705 | Oct 2018 → Feb 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03207750 | Sep 2017 → Oct 2018 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02062385 | May 2014 → Jun 2015 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01375647 | May 2011 → Oct 2014 | Rotavirus infection, tropical sprue | University of Vermont | Completed | No outcome recorded |
| Phase 3 | NCT01825109 | Jul 2010 → Apr 2011 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00718237 | Aug 2008 → Aug 2009 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00496054 | May → Oct 2008 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00533507 | Sep 2007 → Jun 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00480324 | Jun 2007 → Mar 2009 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00362648 | Mar 2007 → Mar 2009 | diarrheal disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00443846 | Feb → Sep 2007 | Rotavirus infection, meningococcal meningitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00420745 | Jan 2007 → Mar 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00396630 | Jan 2007 → Jan 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00329745 | Jan 2007 → Jul 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00363545 | Sep 2006 → Apr 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00258154 | Feb → Nov 2006 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00130832 | Oct 2005 → Jul 2006 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00241644 | Oct 2005 → Jun 2008 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00158756 | Sep 2005 → Nov 2006 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00166517 | Aug 2005 → Jul 2006 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00757770 | Aug 2003 → Jan 2004 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00092456 | May 2003 → Aug 2004 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092443 | Sep 2002 → Jun 2004 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00090233 | Jan 2001 → Oct 2004 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT03587389 | Mar 2019 → Jun 2022 | Rotavirus infection, diarrheal disease | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT02941107 | Mar 2018 → Jul 2026 overdue | Rotavirus infection | Telethon Kids Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02992197 | Jun 2017 → Jun 2018 | Rotavirus infection | University of Vermont | Completed | No outcome recorded |
| Phase 4 | NCT02907216 | Sep 2016 → May 2017 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02286895 | Oct 2014 → Mar 2015 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 4 | NCT02153866 | Dec 2013 → May 2014 | Rotavirus infection | Sichuan Center for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT01926015 | Sep 2013 → Jun 2014 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01841671 | Apr 2013 → May 2014 | poliomyelitis | University of Chile | Unknown | No outcome recorded |
| Phase 4 | NCT01700621 | Jan → Sep 2013 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 4 | NCT01575197 | Sep 2012 → Feb 2013 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 4 | NCT01616693 | Jul 2012 → Jul 2013 | — | PATH | Completed | No outcome recorded |
| Phase 4 | NCT01199874 | Apr 2011 → Sep 2012 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 4 | NCT01266850 | Mar 2011 → Oct 2013 | Rotavirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT01198769 | Nov 2010 → Apr 2011 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00995813 | Dec 2009 → May 2012 | Rotavirus infection, chronic intestinal failure | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00969228 | Aug 2009 → Jul 2010 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00737503 | Sep 2008 → Mar 2011 | Rotavirus infection | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT00740935 | May 2007 → Dec 2010 | Rotavirus infection | University Hospital, Brest | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04123119 | Jan → May 2019 | diarrheal disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 42 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03507738 Comparator | Jul 2018 → Jun 2019 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06647407 Background | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02728869 Comparator | Jun 2016 → Mar 2017 | Rotavirus infection | MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01090453 Background | May 2010 → Oct 2011 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01110044 Background | Apr 2010 → Aug 2012 | Rotavirus infection | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03602053 Comparator | Jan → Oct 2019 | Rotavirus infection, diarrheal disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| Phase 333 trials | ||||||
| Phase 3 | NCT06824181 Background | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Background | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06736041 Background | Dec 2024 → May 2027 expected | — | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06397768 Background | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT05794230 Background | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04010448 Comparator | Oct 2019 → Dec 2025 | Rotavirus infection | PATH | Unknown | No outcome recorded |
| Phase 3 | NCT03620162 Background | Oct 2018 → Dec 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03632720 Background | Oct 2018 → Dec 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03691610 Background | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03673462 Background | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02914184 Comparator | Oct 2016 → Jun 2018 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02584816 Comparator | Nov 2015 → Apr 2017 | Rotavirus infection | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02096263 Background | Apr 2014 → Feb 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01978093 Background | Feb 2014 → Mar 2016 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02193061 Comparator | Nov 2013 → Jun 2017 | Rotavirus infection | National Institute of Pediatrics, Mexico | Completed | No outcome recorded |
| Phase 3 | NCT01983540 Background | Oct 2013 → Jun 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01839188 Background | May 2013 → Mar 2014 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01600092 Comparator | Apr 2013 → Mar 2014 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01839175 Background | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01480258 Background | Nov 2011 → Oct 2013 | bacterial infectious disease, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01345240 Background | Nov 2011 → Jan 2013 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01341639 Background | May 2011 → Mar 2013 | bacterial infectious disease, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01340937 Background | May 2011 → Dec 2012 | bacterial infectious disease, viral infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01337167 Background | Apr 2011 → May 2013 | bacterial infectious disease, viral infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01309646 Background | Mar 2011 → Feb 2012 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01000974 Background | Jun 2010 → Nov 2011 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01003431 Comparator | Dec 2009 → Aug 2010 | Rotavirus infection, diphtheria, pertussis, tetanus | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT00829010 Background | Feb 2009 → Jun 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00808444 Background | Jan → Nov 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00489554 Background | Jul 2007 → Mar 2008 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00420316 Background | Feb → Aug 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00370318 Background | Sep 2006 → Apr 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02847026 Comparator | Sep 2016 → May 2017 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT02542462 Comparator | Nov 2015 → May 2017 | Rotavirus infection, intussusception | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-11-21 | Daiichi Sankyo | Launch of Rotarix(R) oral liquid formulation First vaccine to prevent rotavirus gastroenteritis in Japan daiichisankyo.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 121 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROTARIX | “Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in...” NCT06025695 ↗64“Participating infants were randomized at 6-8 weeks of age to receive either three doses of TV P2-VP8 intramuscularly (IM) plus oral placebo or two doses of ROTARIX® (oral) plus...” PMID 41319434 ↗ Nov 2025 “Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2...” NCT00363545 ↗ “three doses of BRV-PV or two doses of Rotarix® and one dose of placebo were given to healthy infants at 6, 10, and 14 weeks of age.” PMID 30104114 ↗ Aug 2018 “Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine” NCT01825109 ↗ “Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden)” NCT01480258 ↗ “Rotarix™ is in routine use in Zambia administered at 6 and 10 weeks infant age” NCT04123119 ↗ “RotaTeq® Rotarix®” NCT06647407 ↗ “ROTARIX™” NCT02941107 ↗ |
| Known as | GSK444563 | “Rotarix (GSK444563)” NCT02907216 ↗ |
| Known as | HRV | “the human rotavirus vaccine (HRV; Rotarix) given early at 6 and 10 wk of age” PMID 28419095 ↗ Apr 20171“Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.” NCT03621670 ↗ |
| Known as | HRV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00385320 ↗ |
| Known as | Human rotavirus RIX4414 strain vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03632720 ↗ |
| Known as | Human Rotavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01575197 ↗ |
| Known as | Pentavalent rotavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03537508 ↗ |
| Known as | PRV | “Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).” NCT02286895 ↗2“BACKGROUND: The pentavalent rotavirus vaccine (PRV), RotaTeq, can be concomitantly administered with most routine childhood vaccines.” PMID 19209092 ↗ Mar 2009 “The live oral pentavalent rotavirus vaccine (PRV) is well tolerated and highly efficacious against rotavirus gastroenteritis.” PMID 18756184 ↗ Oct 2008 |
| Known as | RIX4414 | “This Phase-IV study evaluated the human rotavirus (RV) vaccine Rotarix (RIX4414) to provide additional local clinical data to the Taiwan Food and Drug Association (NCT01198769).” PMID 24079716 ↗ Jan 2013 |
| Known as | Rotarix vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01700621 ↗ |
| Known as | Rotarix, GlaxoSmithKline UK | “Rotarix®, GlaxoSmithKline UK” NCT02002156 ↗ |
| Known as | RotarixTM | “a 2-dose (RotarixTM) oral rotavirus vaccine will be offered during the study” NCT01841671 ↗ |
| Known as | Rotateq | “Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral,...” NCT00092456 ↗35“BACKGROUND: The pentavalent rotavirus vaccine (PRV), RotaTeq, can be concomitantly administered with most routine childhood vaccines.” PMID 19209092 ↗ Mar 2009 “[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™” NCT01003431 ↗ “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age” PMID 27846055 ↗ Feb 2017 “RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)” NCT01480258 ↗ “Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.” NCT00953056 ↗ “V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)” NCT02062385 ↗ “RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age” NCT03673462 ↗ “Biological: Rotateq™” NCT00090233 ↗ “RotaTeq® Rotarix®” NCT06647407 ↗ |
| Known as | RotaTeq Vaccine | “RotaTeq™ Vaccine” NCT00496054 ↗ |
| Known as | Rotavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794230 ↗ |
| Known as | Rotavirus Vaccine, Live, Oral, Pentavalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03691610 ↗ |
| Known as | Rotavirus Vaccine, Live, Pentavalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630705 ↗ |
| Known as | RV1 | “ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by...” NCT02941107 ↗4“Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) or Rotarix (RV1) at 2, 4months of age and PCV13 at 11-12months.” PMID 27288217 ↗ Jun 2016 “the pentavalent RotaTeq (RV5) and monovalent Rotarix (RV1)” NCT02847026 ↗ “monovalent rotavirus vaccine (Rotarix®, RV1) alone” NCT02542462 ↗ “Rotarix™ (RV1)” PMID 38463163 ↗ Feb 2024 |
| Known as | RV5 | “Since being introduced in routine infant immunization schedules in the United States in 2006, the oral live pentavalent rotavirus vaccine RV5 (RotaTeq™) has contributed to...” PMID 23732903 ↗ May 20136“Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) or Rotarix (RV1) at 2, 4months of age and PCV13 at 11-12months.” PMID 27288217 ↗ Jun 2016 “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age” PMID 27846055 ↗ Feb 2017 “the pentavalent RotaTeq (RV5) and monovalent Rotarix (RV1)” NCT02847026 ↗ “pentavalent rotavirus vaccine (RotaTeq®, RV5)” NCT02542462 ↗ “the live pentavalent rotavirus vaccine (RV5)” PMID 25424929 ↗ 2014 “RotaTeq™ (RV5)” PMID 38463163 ↗ Feb 2024 |
| Known as | V260 | “RotaTeq™ (V260)” NCT01926015 ↗ |
| Modality | Vaccine | “live pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine” PMID 16394299 ↗ Jan 2006 |
| Route | Oral | “administered orally” NCT00090233 ↗ |